Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares OutstandingShort-Term Debt repayments
Ratios

Palisade Bio (PALI) EBIAT (2016 - 2025)

Palisade Bio has reported EBIAT over the past 16 years, most recently at -$8.9 million for Q4 2025.

  • Quarterly EBIAT fell 166.12% to -$8.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$16.8 million through Dec 2025, down 16.23% year-over-year, with the annual reading at -$16.8 million for FY2025, 16.23% down from the prior year.
  • EBIAT was -$8.9 million for Q4 2025 at Palisade Bio, down from -$2.9 million in the prior quarter.
  • Over five years, EBIAT peaked at $8.1 million in Q3 2021 and troughed at -$31.7 million in Q2 2021.
  • The 5-year median for EBIAT is -$3.5 million (2024), against an average of -$4.5 million.
  • The largest YoY upside for EBIAT was 538.8% in 2021 against a maximum downside of 1615.07% in 2021.
  • A 5-year view of EBIAT shows it stood at $8.1 million in 2021, then plummeted by 146.0% to -$3.7 million in 2022, then grew by 20.13% to -$3.0 million in 2023, then fell by 12.55% to -$3.3 million in 2024, then tumbled by 166.12% to -$8.9 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's EBIAT are -$8.9 million (Q4 2025), -$2.9 million (Q3 2025), and -$2.8 million (Q2 2025).